晚期肾癌分子靶向治疗新进展

肾癌是泌尿系最常见的恶性肿瘤，透明细胞癌是常见病理类型，约占全部肾癌的 85 %～90 %。既往主要以化疗、白介素及干扰素药物等治疗肾癌。近年来随着肿瘤诊治水平的提高，对肾癌的认识和诊治取得重要突破，特别是分子靶向治疗为患者提供了新的治疗手段。以索拉非尼、舒尼替尼、帕唑帕尼、贝伐珠单抗、替西罗莫司、依维莫司、阿西替尼和卡博替尼等分子靶向治疗多种药物已应用于临床，为患者带来明显生存获益且耐受性较好。本文主要对晚期肾癌分子靶向治疗方面的最新进展进行综述。

Advances in molecular targeting therapy for advanced kidney cancer

Kidney cancer is one of the most common genitourinary malignant tumors. Renal cell carcinoma, which accounts for ap-proximately 85%-90%of all kidney cancers, is one of the most common pathological types of kidney cancer. In the past, patients with kidney cancer usually received symptomatic treatment, such as chemotherapy, interleukin therapy, and interferon therapy. In recent years, breakthroughs in renal cancer treatment resulted from improved tumor diagnostic and treatment methods. In particular, molec-ular targeting therapy provides a new treatment method for kidney cancer. Currently, sorafenib, sunitinib, pazopanib, bevacizumab, temsirolimus, everolimus, axitinib, and cabozantinib have been approved by the U.S. FDA. A number of medical studies show that mo-lecular targeting therapy confers significant survival benefits to patients while improving tolerability. This article summarizes the latest data in the development of molecular targeting therapy for patients with advanced kidney cancer, providing a reference for clinicians.